Understanding the molecular consequences of inherited muscular dystrophies: advancements through proteomic experimentation

Expert Review of Proteomics

Volumn 13, Issue 7, 2016, Pages 659-671

  Fuller, Heidi R ^a,b   Graham, Laura C ^c,d   Llavero Hurtado, Maica ^c,d   Wishart, Thomas M ^c,d  

^a ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

^b KEELE UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

collagen VI myopathies; Duchenne muscular dystrophy; Emery Dreifuss; facioscapulohumeral muscular dystrophy; inherited neuromuscular disease; limb girdle muscular dystrophy; muscular dystrophy; myotonic dystrophy; Proteomics

Indexed keywords

PROTEIN; PROTEOME; STRUCTURAL PROTEIN; BIOLOGICAL MARKER;

CELLULAR STRESS RESPONSE; COLLAGEN VI MYOPATHY; DATA ANALYSIS; DISEASE COURSE; DUCHENNE MUSCULAR DYSTROPHY; EMERY DREIFUSS MUSCULAR DYSTROPHY; FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY; GENE EXPRESSION PROFILING; HUMAN; IMMUNOCOMPETENT CELL; LIMB GIRDLE MUSCULAR DYSTROPHY; MEMBRANE PERMEABILITY; MOLECULAR PATHOLOGY; MUSCLE; MUSCLE TISSUE; MUSCULAR DYSTROPHY; MYOTONIC DYSTROPHY; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; TISSUE CHARACTERIZATION; GENETICS; PATHOLOGY;

BIOMARKERS; HUMANS; MUSCULAR DYSTROPHIES; PROTEOME; PROTEOMICS;

EID: 84978877889     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1080/14789450.2016.1202768     Document Type: Review

References (100)

1. E.Mercuri, F.Muntoni Muscular dystrophy: new challenges and review of the current clinical trials. Curr Opin Pediatr. 2013;25(6):701–707.
2. P.B.Kang, R.C.Griggs. Advances in muscular dystrophies. JAMA Neurol. 2015;72(7):741–742.
3. S.T.Cooper, S.I.Head. Membrane injury and repair in the muscular dystrophies. Neuroscientist. 2015;21(6):653–668.
4. A.Theadom, M.Rodrigues, R.Roxburgh, et al. Prevalence of muscular dystrophies: a systematic literature review. Neuroepidemiology. 2014;43(3–4):259–268.
5. J.K.Mah, L.Korngut, K.M.Fiest, et al. A systematic review and meta-analysis on the epidemiology of the muscular dystrophies. Can J Neurol Sci. 2016;43(1):163–177.
6. C.Barakat-Haddad, S.Shin, H.Candundo, et al. A systematic review of risk factors associated with muscular dystrophies. Neurotoxicology. 2016. doi:10.1016/j.neuro.2016.03.007
7. M.H.Choi, J.R.Ow, N.-D.Yang, et al. Oxidative stress-mediated skeletal muscle degeneration: molecules, mechanisms, and therapies. Oxid Med Cell Longev. 2016;2016:1–13.
8. J.K.Mah, L.Korngut, J.Dykeman, et al. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014;24(6):482–491.
9. E.P.Hoffman, R.H.BrownJr, L.M.Kunkel. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987;51(6):919–928.
10. M.S.Falzarano, C.Scotton, C.Passarelli, et al. Duchenne muscular dystrophy: from diagnosis to therapy. Molecules. 2015;20(10):18168–18184.
11. A.H.Vo, E.M.McNally. Modifier genes and their effect on Duchenne muscular dystrophy. Curr Opin Neurol. 2015;28(5):528–534.
12. R.J.Fairclough, K.J.Perkins, K.E.Davies. Pharmacologically targeting the primary defect and downstream pathology in Duchenne muscular dystrophy. Curr Gene Ther. 2012;12(3):206–244.
13. F.Forner, S.Furlan, S.Salvatori. Mass spectrometry analysis of complexes formed by myotonic dystrophy protein kinase (DMPK). Biochim Biophys Acta. 2010;1804(6):1334–1341.
14. D.H.Cho, S.J.Tapscott. Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Biochim Biophys Acta. 2007;1772(2):195–204.
15. O.Hernández-Hernández, C.Guiraud-Dogan, G.Sicot, et al. Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behaviour. Brain. 2013;136(Pt 3):957–970.
16. R.S.Savkur, A.V.Philips, T.A.Cooper. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet. 2001;29(1):40–47.
17. R.S.Savkur, A.V.Philips, T.A.Cooper, et al. Insulin receptor splicing alteration in myotonic dystrophy type 2. Am J Hum Genet. 2004;74(6):1309–1313.
18. B.Celegato, D.Capitanio, M.Pescatori, et al. Parallel protein and transcript profiles of FSHD patient muscles correlate to the D4Z4 arrangement and reveal a common impairment of slow to fast fibre differentiation and a general deregulation of MyoD-dependent genes. Proteomics. 2006;6(19):5303–5321.
19. C.L.Himeda, T.I.Jones, P.L.Jones. Facioscapulohumeral muscular dystrophy as a model for epigenetic regulation and disease. Antioxid Redox Signal. 2015;22(16):1463–1482.
20. A.Tassin, B.Leroy, D.Laoudj-Chenivesse, et al. FSHD myotubes with different phenotypes exhibit distinct proteomes. PLoS One. 2012;7(12):e51865.
21. D.Laoudj-Chenivesse, G.Carnac, C.Bisbal, et al. Increased levels of adenine nucleotide translocator 1 protein and response to oxidative stress are early events in facioscapulohumeral muscular dystrophy muscle. J Mol Med (Berl). 2005;83(3):216–224.
22. V.Straub, M.Bertoli. Where do we stand in trial readiness for autosomal recessive limb girdle muscular dystrophies? Neuromuscul Disord. 2016;26(2):111–125.
23. A.E.Emery. Population frequencies of inherited neuromuscular diseases–a world survey. Neuromuscul Disord. 1991;1(1):19–29.
24. I.Richard, O.Broux, V.Allamand, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell. 1995;81(1):27–40.
25. M.Fanin, A.C.Nascimbeni, L.Fulizio, et al. Loss of calpain-3 autocatalytic activity in LGMD2A patients with normal protein expression. Am J Pathol. 2003;163(5):1929–1936.
26. A.Lek, F.J.Evesson, F.A.Lemckert, et al. Calpains, cleaved mini-dysferlinC72, and L-type channels underpin calcium-dependent muscle membrane repair. J Neurosci. 2013;33(12):5085–5094.
27. J.Liu, M.Aoki, I.Illa, et al. Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb girdle muscular dystrophy. Nat Genet. 1998;20(1):31–36.
28. D.Bansal, K.Miyake, S.S.Vogel, et al. Defective membrane repair in dysferlin-deficient muscular dystrophy. Nature. 2003;423(6936):168–172.
29. G.Bonne, M.R.Di Barletta, S.Varnous, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet. 1999;21(3):285–288.
30. A.Muchir, G.Bonne, A.J.van der Kooi, et al. Identification of mutations in the gene encoding lamins A/C in autosomal dominant limb girdle muscular dystrophy with atrioventricular conduction disturbances (LGMD1B). Hum Mol Genet. 2000;9(9):1453–1459.
31. S.Bione, E.Maestrini, S.Rivella, et al. Identification of a novel X-linked gene responsible for Emery-Dreifuss muscular dystrophy. Nat Genet. 1994;8(4):323–327.
32. V.Dubowitz. Muscle disorders in childhood. 2nd ed. London: Saunders; 1995.
33. G.Bonne, R.B.Yaou, C.Beroud, et al. 108th ENMC International Workshop, 3rd Workshop of the MYO-CLUSTER project: EUROMEN, 7th international Emery-Dreifuss muscular dystrophy (EDMD) Workshop, 13–15 September 2002, Naarden, The Netherlands. Neuromuscul Disord. 2003;13(6):508–515.
34. M.P.Menezes, L.B.Waddell, F.J.Evesson, et al. Importance and challenge of making an early diagnosis in LMNA-related muscular dystrophy. Neurology. 2012;78(16):1258–1263.
35. D.-A.M.Pillers, N.H.Von Bergen. Emery-Dreifuss muscular dystrophy: a test case for precision medicine. Appl Clin Genet. 2016;9:27–32.
36. M.Raffae le Di Barletta, E.Ricci, G.Galluzzi, et al. Different mutations in the LMNA gene cause autosomal dominant and autosomal recessive Emery-Dreifuss muscular dystrophy. Am J Hum Genet. 2000;66(4):1407–1412.
37. D.Rajgor, C.M.Shanahan. Nesprins: from the nuclear envelope and beyond. Expert Rev Mol Med. 2013;15:e5.
38. H.Furthmayr, H.Wiedemann, R.Timpl, et al. Electron-microscopical approach to a structural model of intima collagen. Biochem J. 1983;211(2):303–311.
39. S.De Palma, D.Capitanio, M.Vasso, et al. Muscle proteomics reveals novel insights into the pathophysiological mechanisms of collagen VI myopathies. J Proteome Res. 2014;13(11):5022–5030.
40. J.Bethlem, G.K.Wijngaarden. Benign myopathy, with autosomal dominant inheritance. A report on three pedigrees. Brain. 1976;99(1):91–100.
41. O.Camacho Vanegas, E.Bertini, R.Z.Zhang, et al. Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proc Natl Acad Sci U S A. 2001;98(13):7516–7521.
42. L.Merlini, L.Morandi, C.Granata, et al. Bethlem myopathy: early-onset benign autosomal dominant myopathy with contractures. Description of two new families. Neuromuscul Disord. 1994;4(5–6):503–511.
43. A.K.Lampe, K.M.Bushby. Collagen VI related muscle disorders. J Med Genet. 2005;42(9):673–685.
44. G.Pepe, E.Bertini, P.Bonaldo, et al. Bethlem myopathy (BETHLEM) and Ullrich scleroatonic muscular dystrophy: 100th ENMC international workshop, 23–24 November 2001, Naarden, The Netherlands. Neuromuscul Disord. 2002;12(10):984–993.
45. E.Demir, P.Sabatelli, V.Allamand, et al. Mutations in COL6A3 cause severe and mild phenotypes of Ullrich congenital muscular dystrophy. Am J Hum Genet. 2002;70(6):1446–1458.
46. G.J.Jöbsis, J.M.Boers, P.G.Barth, et al. Bethlem myopathy: a slowly progressive congenital muscular dystrophy with contractures. Brain. 1999;122 (Pt 4)(Pt 4):649–655.
47. F.Cynthia Martin, M.Hiller, P.Spitali, et al. Fibronectin is a serum biomarker for Duchenne muscular dystrophy. Proteomics Clin Appl. 2014;8(3–4):269–278.
48. J.Rouillon, A.Zocevic, T.Leger, et al. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy. Neuromuscul Disord. 2014;24(7):563–573.
49. L.Guevel, J.R.Lavoie, C.Perez-Iratxeta, et al. Quantitative proteomic analysis of dystrophic dog muscle. J Proteome Res. 2011;10(5):2465–2478.
50. Y.Ge, M.P.Molloy, J.S.Chamberlain, et al. Proteomic analysis of mdx skeletal muscle: great reduction of adenylate kinase 1 expression and enzymatic activity. Proteomics. 2003;3(10):1895–1903.
51. H.B.Sarnat. Vimentin and desmin in maturing skeletal muscle and developmental myopathies. Neurology. 1992;42(8):1616–1624.
52. A.Gallanti, A.Prelle, M.Moggio, et al. Desmin and vimentin as markers of regeneration in muscle diseases. Acta Neuropathol. 1992;85(1):88–92.
53. J.Y.Shim, T.S.Kim. Relationship between utrophin and regenerating muscle fibers in duchenne muscular dystrophy. Yonsei Med J. 2003;44(1):15–23.
54. A.Holland, M.Henry, P.Meleady, et al. Comparative label-free mass spectrometric analysis of mildly versus severely affected mdx mouse skeletal muscles identifies annexin, lamin, and vimentin as universal dystrophic markers. Molecules. 2015;20(6):11317–11344.
55. C.Lewis, K.Ohlendieck. Proteomic profiling of naturally protected extraocular muscles from the dystrophin-deficient mdx mouse. Biochem Biophys Res Commun. 2010;396(4):1024–1029.
56. A.Holland, P.Dowling, P.Meleady, et al. Label-free mass spectrometric analysis of the mdx-4cv diaphragm identifies the matricellular protein periostin as a potential factor involved in dystrophinopathy-related fibrosis. Proteomics. 2015;15(13):2318–2331.
57. H.Brinkmeier, K.Ohlendieck. Chaperoning heat shock proteins: proteomic analysis and relevance for normal and dystrophin-deficient muscle. Proteomics Clin Appl. 2014;8(11–12):875–895.
58. R.W.R.Dudley, M.Khairallah, S.Mohammed, et al. Dynamic responses of the glutathione system to acute oxidative stress in dystrophic mouse (mdx) muscles. Am J Phys Regul Integr Comp Phys. 2006;291(3):R704–R710.
59. R.Renjini, N.Gayathri, A.Nalini, et al. Oxidative damage in muscular dystrophy correlates with the severity of the pathology: role of glutathione metabolism. Neurochem Res. 2012;37(4):885–898.
60. L.Khouzami, M.-C.Bourin, C.Christov, et al. Delayed cardiomyopathy in dystrophin deficient mdx mice relies on intrinsic glutathione resource. Am J Pathol. 2010;177(3):1356–1364.
61. M.E.Murphy, J.P.Kehrer. Activities of antioxidant enzymes in muscle, liver and lung of chickens with inherited muscular dystrophy. Biochem Biophys Res Commun. 1986;134(2):550–556.
62. D.G.Allen, N.P.Whitehead. Duchenne muscular dystrophy–what causes the increased membrane permeability in skeletal muscle? Int J Biochem Cell Biol. 2011;43(3):290–294.
63. P.L.McNeil, R.Khakee. Disruptions of muscle fiber plasma membranes. Role in exercise-induced damage. Am J Pathol. 1992;140(5):1097–1109.
64. H.Amthor, T.Egelhof, I.McKinnell, et al. Albumin targeting of damaged muscle fibres in the mdx mouse can be monitored by MRI. Neuromuscul Disord. 2004;14(12):791–796.
65. E.E.Dupont-Versteegden, A.M.Kitten, M.S.Katz, et al. Elevated levels of albumin in soleus and diaphragm muscles of mdx mice. Proc Soc Exp Biol Med Soc Exp Biol Medicine New York. 1996;213(3):281–286.
66. Y.Hathout, R.L.Marathi, S.Rayavarapu, et al. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. Hum Mol Genet. 2014;23(24):6458–6469.
67. I.Niebrój-Dobosz, M.Lukasiuk. Immunoblot analysis of sarcoplasmic calcium binding proteins in Duchenne muscular dystrophy. J Neurol. 1995;242(2):82–86.
68. M.Sano, T.Yokota, T.Endo, et al. A developmental change in the content of parvalbumin in normal and dystrophic mouse (mdx) muscle. J Neurol Sci. 1990;97(2–3):261–272.
69. A.Vallejo-Illarramendi, I.Toral-Ojeda, G.Aldanondo, et al. Dysregulation of calcium homeostasis in muscular dystrophies. Expert Rev Mol Med. 2014;16:e16.
70. S.A.Villalta, A.S.Rosenberg, J.A.Bluestone. The immune system in Duchenne muscular dystrophy: friend or foe. Rare Dis (Austin, TX). 2015;3(1):e1010966.
71. Y.Ge, M.P.Molloy, J.S.Chamberlain, et al. Differential expression of the skeletal muscle proteome in mdx mice at different ages. Electrophoresis. 2004;25(15):2576–2585.
72. P.Doran, P.Dowling, P.Donoghue, et al. Reduced expression of regucalcin in young and aged mdx diaphragm indicates abnormal cytosolic calcium handling in dystrophin-deficient muscle. Biochim Biophys Acta. 2006;1764(4):773–785.
73. P.Doran, G.Martin, P.Dowling, et al. Proteome analysis of the dystrophin-deficient MDX diaphragm reveals a drastic increase in the heat shock protein cvHSP. Proteomics. 2006;6(16):4610–4621.
74. S.Carberry, H.Brinkmeier, Y.Zhang, et al. Comparative proteomic profiling of soleus, extensor digitorum longus, flexor digitorum brevis and interosseus muscles from the mdx mouse model of Duchenne muscular dystrophy. Int J Mol Med. 2013;32(3):544–556.
75. A.Holland, P.Dowling, M.Zweyer, et al. Proteomic profiling of cardiomyopathic tissue from the aged mdx model of Duchenne muscular dystrophy reveals a drastic decrease in laminin, nidogen and annexin. Proteomics. 2013;13(15):2312–2323.
76. S.Carberry, M.Zweyer, D.Swandulla, et al. Profiling of age-related changes in the tibialis anterior muscle proteome of the mdx mouse model of dystrophinopathy. J Biomed Biotechnol. 2012;2012:1–11.
77. S.Carberry, M.Zweyer, D.Swandulla, et al. Proteomics reveals drastic increase of extracellular matrix proteins collagen and dermatopontin in the aged mdx diaphragm model of Duchenne muscular dystrophy. Int J Mol Med. 2012;30(2):229–234.
78. M.Gomes-Pereira, L.Foiry, A.Nicole, et al. CTG trinucleotide repeat “big jumps”: large expansions, small mice. PLoS Genet. 2007;3(4):e52.
79. H.Seznec, A.S.Lia-Baldini, C.Duros, et al. Transgenic mice carrying large human genomic sequences with expanded CTG repeat mimic closely the DM CTG repeat intergenerational and somatic instability. Hum Mol Genet. 2000;9(8):1185–1194.
80. S.M.Carpanini, L.McKie, D.Thomson, et al. A novel mouse model of Warburg Micro syndrome reveals roles for RAB18 in eye development and organisation of the neuronal cytoskeleton. Dis Model Mech. 2014;7(6):711–722.
81. C.De La Torre, I.Illa, G.Faulkner, et al. Proteomics identification of differentially expressed proteins in the muscle of dysferlin myopathy patients. Proteomics Clin Appl. 2009;3(4):486–497.
82. C.Magagnotti, A.Bachi, G.Zerbini, et al. Protein profiling reveals energy metabolism and cytoskeletal protein alterations in LMNA mutation carriers. Biochim Biophys Acta. 2012;1822(6):970–979.
83. S.De Palma, L.Morandi, E.Mariani, et al. Proteomic investigation of the molecular pathophysiology of dysferlinopathy. Proteomics. 2006;6(1):379–385.
84. T.M.Wishart, C.A.Mutsaers, M.Riessland, et al. Dysregulation of ubiquitin homeostasis and β-catenin signaling promote spinal muscular atrophy. J Clin Invest. 2014;124(4):1821–1834.
85. S.L.Eaton, S.L.Roche, M.Llavero Hurtado, et al. Total protein analysis as a reliable loading control for quantitative fluorescent Western blotting. PLoS One. 2013;8(8):e72457.
86. A.M.L.Coenen-Stass, G.McClorey, R.Manzano, et al. Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics. Sci Rep. 2015;5:17014.
87. C.A.Mutsaers, D.J.Lamont, G.Hunter, et al. Label-free proteomics identifies Calreticulin and GRP75/Mortalin as peripherally accessible protein biomarkers for spinal muscular atrophy. Genome Med. 2013;5(10):95.
88. A.Aghamaleky Sarvestany, G.Hunter, A.Tavendale, et al. Label-free quantitative proteomic profiling identifies disruption of ubiquitin homeostasis as a key driver of Schwann cell defects in spinal muscular atrophy. J Proteome Res. 2014;13(11):4546–4557.
89. T.C.Roberts, H.J.Johansson, G.McClorey, et al. Multi-level omics analysis in a murine model of dystrophin loss and therapeutic restoration. Hum Mol Genet. 2015;24(23):6756–6768.
90. S.Murphy, M.Henry, P.Meleady, et al. Simultaneous pathoproteomic evaluation of the dystrophin-glycoprotein complex and secondary changes in the mdx-4cv mouse model of Duchenne muscular dystrophy. Biology. 2015;4(2):397–423.
91. S.Carberry, M.Zweyer, D.Swandulla, et al. Application of fluorescence two-dimensional difference in-gel electrophoresis as a proteomic biomarker discovery tool in muscular dystrophy research. Biology. 2013;2(4):1438–1464.
92. D.Gardan-Salmon, J.M.Dixon, S.M.Lonergan, et al. Proteomic assessment of the acute phase of dystrophin deficiency in mdx mice. Eur J Appl Physiol. 2011;111(11):2763–2773.
93. S.Murphy, M.Zweyer, M.Henry, et al. Label-free mass spectrometric analysis reveals complex changes in the brain proteome from the mdx-4cv mouse model of Duchenne muscular dystrophy. Clin Proteomics. 2015;12:27.
94. S.Murphy, P.Dowling, M.Zweyer, et al. Proteomic analysis of dystrophin deficiency and associated changes in the aged mdx-4cv heart model of dystrophinopathy-related cardiomyopathy. J Proteomics. 2016 Mar 4. pii: S1874-3919(16)30065-3. doi:10.1016/j.jprot.2016.03.011
95. P.Doran, S.D.Wilton, S.Fletcher, et al. Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm. Proteomics. 2009 Feb;9(3):671–685.
96. S.Rayavarapu, W.Coley, E.Cakir, et al. Identification of disease specific pathways using in vivo SILAC proteomics in dystrophin deficient mdx mouse. Mol Cell Proteomics. 2013;12(5):1061–1073.
97. M.K.Gulston, D.V.Rubtsov, H.J.Atherton, et al. A combined metabolomic and proteomic investigation of the effects of a failure to express dystrophin in the mouse heart. J Proteome Res. 2008 May;7(5):2069–2077.
98. H.R.Fuller, T.H.Gillingwater, T.M.Wishart. Commonality amid diversity: multi-study proteomic identification of conserved disease mechanisms in spinal muscular atrophy. Neuromuscular Disord. 2016. doi:10.1016/j.nmd.2016.06.004.
99. S.Duguez, W.Duddy, H.Johnston, et al. Dystrophin deficiency leads to disturbance of LAMP1-vesicle-associated protein secretion. Cell Mol Life Sci. 2013;70(12):2159–2174.
100. S.Carberry, M.Zweyer, D.Swandulla, et al. Comparative proteomic analysis of the contractile-protein-depleted fraction from normal versus dystrophic skeletal muscle. Anal Biochem. 2014;446:108–115.